New frontiers for cell and gene therapy: addressing 2024 milestones and the outlook for 2025

The panel (from left to right): Alexey Bersenev MD PhD, Director, Cell Therapy Labs, Yale New Haven Hospital, and Assistant Professor, Yale University; Florence Salmon, VP Regulatory Affairs, HOOKIPA Pharma Inc.; Jason Dowd, Global Lead Cell Therapy Platform Process, Bayer; Chris Bond PhD, Chief Scientific Officer, Notch Therapeutics, Inc.We bring you insights from four experts across the cell and gene therapy industry, who reflect on the key events of 2024 and share their thoughts on what lies ahead for 2025. From the approval of innovative therapies, such as locally made CAR-T products and new cellular immunotherapy treatments for solid cancers, to breakthroughs in gene delivery methods, 2024 saw many milestones for the field. Looking forward to 2025, there’s a shared sense of excitement about transformative clinical data and advancements that could pave the way for new, large-scale therapeutic applications.